Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus K 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus K 10.
K-LEASE vs K+10
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
Potassium ion replacement; essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance.
Hypokalemia prevention and treatmentDigitalis intoxication with hypokalemia
Treatment and prevention of hypokalemiaDigitalis intoxication
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
IV: 10 mEq potassium chloride infused at a rate not exceeding 10 mEq/hour via peripheral line; maximum 20 mEq/hour via central line with continuous ECG monitoring. Oral: 20-40 mEq per day in divided doses; maximum 100 mEq per day.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
Potassium does not have a true elimination half-life as it is an endogenous ion under homeostatic control. However, intravenously administered potassium has a distribution half-life of approximately 1-1.5 hours and a slow terminal phase reflecting cellular redistribution and eventual excretion. Clinical context: The apparent half-life is highly dependent on renal function and body stores.
Not metabolized; renally excreted as potassium ion.
Primarily excreted unchanged by the kidneys (90%); small amount excreted in feces. Not metabolized.
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Potassium is primarily excreted via the kidneys (approximately 90%) with the remainder lost in feces (via colonic secretion). In patients with normal renal function, urinary potassium excretion accounts for >90% of elimination. Fecal excretion is minimal (≤10%) but increases in renal impairment.
Not protein bound (0%). Potassium is a free ion.
Potassium is not significantly bound to plasma proteins. It is essentially free in plasma (0% protein binding).
0.33 L/kg (total body water); clinical meaning: potassium distributes throughout total body water, but primarily intracellular (98% intracellular).
Vd: Approximately 0.5 L/kg (range 0.4-0.6 L/kg). This reflects distribution primarily into the extracellular fluid compartment, with subsequent slow equilibration into the intracellular space. Clinical meaning: The Vd is small, indicating that potassium remains largely in the ECF and is not extensively tissue-bound initially.
Oral: 100% (as potassium chloride; fully absorbed).
Oral: Potassium chloride solutions have bioavailability near 100% as they are completely absorbed. Solid oral formulations (tablets, capsules) have variable bioavailability depending on dissolution and release characteristics; enteric-coated products may have reduced bioavailability (80-90%). Intravenous: 100%.
GFR 20-49 mL/min: reduce dose by 50%; GFR <20 mL/min: contraindicated.
GFR > 50 mL/min: no adjustment. GFR 10-50 mL/min: reduce dose by 50%; monitor serum potassium frequently. GFR < 10 mL/min: contraindicated unless serum potassium < 5.0 mEq/L and dialysis available.
Child-Pugh A: no adjustment; Child-Pugh B/C: contraindicated due to risk of encephalopathy.
No specific Child-Pugh dose adjustment required; monitor serum potassium and acid-base status due to risk of hyperkalemia in cirrhosis.
1-3 mEq/kg/day in divided doses with meals; maximum 3 mEq/kg/day.
IV: 0.5-1 mEq/kg/dose up to 10 mEq per dose, infused at ≤0.5 mEq/kg/hour; maximum 1 mEq/kg/hour with cardiac monitoring. Oral: 1-2 mEq/kg/day in divided doses; maximum 3 mEq/kg/day. Use with caution in neonates.
Start at lower end of dosing range (25 mEq/day) due to decreased renal function and increased sensitivity to hyperkalemia.
Initiate at low end of adult dosing (e.g., 10-20 mEq/day oral); reduce infusion rate to ≤10 mEq/hour IV; monitor renal function and serum potassium closely due to age-related decreased GFR and increased sensitivity.
None
Potassium supplements can cause hyperkalemia and cardiac arrest. Use with extreme caution in patients with conditions predisposing to hyperkalemia. Monitor serum potassium levels and ECG regularly.
["Hyperkalemia risk especially in renal impairment","Cardiac arrest if given too rapidly","Monitor serum potassium and ECG during administration"]
Risk of hyperkalemia, especially with renal impairment, diabetes, or concurrent use of potassium-sparing diuretics or ACE inhibitors. Avoid rapid intravenous administration. Use with caution in patients with cardiac disease or those receiving digitalis.
["Hyperkalemia","Severe renal impairment with oliguria or anuria","Addison's disease","Adynamic ileus","Concurrent use with potassium-sparing diuretics"]
Hyperkalemia, severe renal impairment with oliguria or azotemia, untreated Addison's disease, acute dehydration, heat cramps, and patients receiving potassium-sparing diuretics or aldosterone antagonists.
Data Pending Review
Data Pending Review
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes) unless directed. Consume low-potassium diet as advised. Do not take with calcium-containing foods or supplements; separate by at least 6 hours.
Avoid excessive intake of high-potassium foods (bananas, oranges, potatoes, spinach, tomatoes, avocados, dried fruits, beans, nuts) and salt substitutes containing potassium chloride, as these may increase the risk of hyperkalemia.
FDA Pregnancy Category C. First trimester: limited human data, animal studies show potential for fetal harm; avoid unless benefit outweighs risk. Second trimester: risk of hypocalcemia and arrhythmias in fetus if maternal potassium abnormal. Third trimester: possible fetal hyperkalemia if maternal overdose; monitor neonatal potassium levels.
Potassium chloride (K+10) is FDA pregnancy category C. No adequate well-controlled studies in pregnant women. In first trimester, no evidence of teratogenicity from animal studies; however, high doses may cause maternal hyperkalemia with potential fetal effects due to altered maternal physiology. In second and third trimesters, risk primarily from maternal electrolyte imbalance. Avoid in severe hyperkalemia as it may cross placenta.
Not recommended during breastfeeding. M/P ratio unknown. Insufficient human data; potential for adverse effects in nursing infant (e.g., hyperkalemia, arrhythmias).
Potassium is a normal component of human milk; supplementation unlikely to cause harm. M/P ratio not established but assumed to be ~1 due to passive distribution. Use caution with high doses (e.g., 10 mEq) as theoretical risk of hyperkalemia in infant if maternal levels elevated. Monitor infant for signs of hyperkalemia only if maternal dose high or renal impairment.
No standard dose adjustments recommended. Monitor serum potassium closely; dose may need reduction due to increased plasma volume and GFR in pregnancy. Individualize based on potassium levels.
Increased plasma volume in pregnancy may reduce serum potassium concentration, potentially requiring higher doses to maintain normokalemia. However, dose adjustments should be guided by serum potassium levels rather than empirical changes. Monitor every 1-2 weeks initially. No specific pharmacokinetic studies; standard adult dose (10 mEq) may be insufficient in severe deficiency due to dilution, but caution to avoid hyperkalemia in cases of decreased renal function (common in preeclampsia).
Category C
Category C
K-LEASE (calcium polystyrene sulfonate) is a potassium-binding resin used for hyperkalemia. Administer orally or rectally; ensure bowel movements to avoid impaction. Monitor serum potassium frequently. Not for rapid correction of life-threatening hyperkalemia. Use with caution in patients with constipation or gastrointestinal surgery.
K+10 is potassium chloride 10 mEq for hypokalemia. Administer orally with food to reduce GI irritation. Never give IV push; must be diluted in appropriate IV fluid and infused at a rate not exceeding 10-20 mEq/hour. ECG monitoring is essential during IV administration due to risk of hyperkalemia and arrhythmias. Use with caution in renal impairment and in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics. Maximum oral dose: 40 mEq per day in divided doses unless severe deficiency.
Take this medication exactly as prescribed, usually 1-4 times daily.Mix powder with water or juice as directed; do not take dry.Stay hydrated and report constipation, abdominal pain, or bloody stools.Do not use laxatives or antacids containing magnesium or aluminum without consulting your doctor.This medication works slowly; it is not for emergency potassium lowering.
Take this medication with a full glass of water or food to prevent stomach upset.Do not crush or chew extended-release tablets; swallow them whole.Do not use salt substitutes containing potassium without your doctor's approval.Report symptoms of hyperkalemia such as muscle weakness, tingling, or irregular heartbeat.Keep a consistent dietary potassium intake; avoid high-potassium foods unless directed by your physician.